FDA criticizes Genzyme study of leukemia drug Clolar Aug 29, 2009
FDA criticizes Genzyme study of leukemia drug ... Just days before a key meeting to consider Genzyme Corp. s application for a new leukemia drug to treat older patients, the Food and Drug Administration released a briefing document criticizing the Cambridge biotechnology company s clinical study of the drug, called Clolar ... Genzyme said the drug deserves to be approved to treat adult acute myeloid leukemia in people who aren t healthy enough to undergo chemotherapy, citing results of its study... (Boston Globe)
Hana Biosciences Announces Second Quarter 2009 Results Aug 15, 2009
Achieved target enrollment of 56 evaluable subjects in the pivotal Phase 2 rALLy clinical trial for the treatment of adult acute lymphoblastic leukemia in second relapse ... Marqibo(r) potentially treats acute lymphoblastic leukemia and lymphomas. (Primezone Releases)
Critical Outcome Technologies Inc. Reports Financial Results for the Fourth Quarter and the Year Ended April 30, 2009 Jul 16, 2009
In May 2008 - announced that patents to its novel drug candidates for the treatment of acute leukemias had been granted by the European Patent Office ... Currently, six targeted libraries of lead compounds are under active development; small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, adult acute leukemia, colorectal cancer and alzheimer's disease. (CCNMatthews Press Releases)
Obama nominates geneticist to head health agency Jul 9, 2009
Using that technique, he and his group subsequently identified the genes for Huntington's disease, neurofibromatosis, multiple endocrine neoplasia type 1 (a tumor of the parathyroid and pituitary glands) and the M4 type of adult acute leukemia. Collins replaced James Watson as head of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health in 1993. (Xinhuanet, China)
